IRCCS C Mondino Institute of Neurology Foundation, Department of Neurology, via Mondino 2, Pavia, Italy.
Expert Opin Drug Metab Toxicol. 2009 Dec;5(12):1587-98. doi: 10.1517/17425250903410226.
Migraine is a multifactorial chronic central nervous system disorder, characterized by recurrent disabling attacks of moderate-to-severe headache. Symptomatic acute treatment of migraine should provide rapid and effective relief of the headache pain. The introduction of the 5-HT(1B/1D) receptor agonists (triptans) expanded the armamentarium for acute migraine pain treatment. Eletriptan is a second-generation triptan with favorable bioavailability and half-life, a high affinity for 5-HT(1B/1D) receptors and selectivity for cranial arteries. Eletriptan (40 and 80 mg) has been shown to be effective as early as 30 min after administration and well tolerated when compared to placebo. In comparative clinical trials, eletriptan 40 and 80 mg were superior or equivalent to other triptans and have shown a very high safety and tolerability profile across the studies performed. Eletriptan showed the most favorable cost-effectiveness profile when compared with other agents in its class.
偏头痛是一种多因素的慢性中枢神经系统疾病，其特征是反复发作的中度至重度头痛导致失能性发作。偏头痛的症状性急性治疗应迅速有效地缓解头痛。5-HT(1B/1D)受体激动剂（曲普坦类药物）的引入扩大了急性偏头痛疼痛治疗的手段。依来曲普坦是第二代曲普坦类药物，具有良好的生物利用度和半衰期，对 5-HT(1B/1D)受体具有高亲和力和对颅动脉的选择性。依来曲普坦（40 和 80mg）在给药后 30 分钟内即可显示出疗效，与安慰剂相比耐受性良好。在比较性临床试验中，依来曲普坦 40mg 和 80mg 优于或等同于其他曲普坦类药物，并且在已完成的研究中表现出非常高的安全性和耐受性。与同类药物相比，依来曲普坦具有最有利的成本效益比。
